Wells Fargo assumed coverage of NeuroPace (NPCE) with an Overweight rating and $19 price target The firm is maintaining the current rating, price target and estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
- Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
- NeuroPace reports Q4 EPS (8c), consensus (17c)
- NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
- NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M